Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting
- 26 January 2010
- journal article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 19 (1), 131-140
- https://doi.org/10.1007/s00520-009-0797-x
Abstract
Chemotherapy-induced nausea and vomiting (CINV), common adverse events of chemotherapy, may be associated with considerable healthcare resource utilization. This study was conducted to describe CINV-associated healthcare visits and costs following a first cycle of highly or moderately emetogenic chemotherapy (HEC or MEC). This retrospective cohort study used the Premier Perspective™ Database to identify adult patients who received their first HEC or MEC and at least one antiemetic agent from 2003 to 2007 at US hospital-based outpatient facilities. Hospital visits with a CINV-related ICD-9 diagnosis were included from the chemotherapy administration date to 30 days later or 1 day before the second chemotherapy, whichever was first. CINV costs were hospital-reported costs. Of 19,139 patients (HEC, 16%; MEC, 84%), mean (SD) age was 59 (14) years; 59% were female; 66% were white. CINV prophylaxis included 5-HT3 antagonists (85%), dexamethasone (76%), and NK-1 antagonists (2%). Overall, 13.8% of patients had a CINV-associated visit (HEC, 18%; MEC, 13%): 0.2% for acute CINV (day of chemotherapy, excluding chemotherapy administration visit) and 13.7% for delayed CINV. CINV-associated visits included inpatient (IP, 64%), outpatient (OP, 26%), and emergency room (ER, 10%) visits. Mean (SD) costs of CINV visits were $5,299 ($6,639); for IP, $7,448 ($7,271); OP, $1,494 ($2,172); and ER, $918 ($1,071). Mean per-patient CINV-associated costs across all patients were $731 ($3,069). Sensitivity analysis excluding visits where CINV was a secondary diagnosis code resulted in a CINV incidence of 4.4%, a mean CINV visit cost of $4,043, and a mean per-patient CINV-associated cost across all patients of $176. CINV visits in the first HEC or MEC cycle were common and costly, especially inpatient hospitalizations in the delayed phase. Strategies to reduce CINV in the delayed phase could reduce healthcare utilization and costs.Keywords
This publication has 22 references indexed in Scilit:
- A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centreSupportive Care in Cancer, 2007
- American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006Journal of Clinical Oncology, 2006
- Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus ConferenceAnnals of Oncology, 2005
- Chemotherapy-Induced Emesis: Quality of Life and Economic Impact in the Context of Current Practice in CanadaSupportive Cancer Therapy, 2005
- Use of complementary and alternative medicine in cancer patients: a European surveyAnnals Of Oncology, 2005
- Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomesSupportive Care in Cancer, 2005
- Derivation of malignancy status from ICD-9 codes.2003
- Costs of Treating and Preventing Nausea and Vomiting in Patients Receiving ChemotherapyJournal of Clinical Oncology, 1999
- Initial control of chemotherapy-induced nausea and vomiting in patient quality of life.1998
- Simplified Calculation of Body-Surface AreaThe New England Journal of Medicine, 1987